Havrix Junior

Havrix Junior is a prescription‑only injectable vaccine that contains an inactivated hepatitis A virus adsorbed on aluminium hydroxide, formulated as a sterile solution for intramuscular or subcutaneous administration. Produced for the EU market, the product does not list a specific strength, and it is classified as an inactivated viral vaccine used for hepatitis A prophylaxis. It is intended for use in children and is supplied in a single‑dose vial.

Havrix Junior is indicated for the active immunisation of children against hepatitis A infection.

- Primary prophylaxis for hepatitis A in children according to recommended immunisation schedules. - Administration as part of a two‑dose series, typically spaced 6–12 months apart. - Use in travelers to regions where hepatitis A is endemic, when age‑appropriate. - Supplemental protection for children with underlying liver disease who are at higher risk. - May be given to children who have not previously received a hepatitis A vaccine.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines. These reactions are generally self‑limiting and resolve without medical intervention.

Common: - Mild pain, redness or swelling at the injection site. - Low‑grade fever within 24 hours after vaccination. - Transient headache or fatigue. - Mild gastrointestinal discomfort such as nausea. - Muscle aches or mild arthralgia. - Transient rash or mild itching.

Serious: - Allergic reactions ranging from urticaria to anaphylaxis. - Neurologic events such as Guillain‑Barré syndrome, reported rarely.

Before administering Havrix Junior, healthcare providers should review the following precautions to ensure safe use in pediatric patients.

- Defer vaccination in children with a known severe allergy to any vaccine component, including aluminium salts. - Postpone dosing in individuals experiencing moderate or severe acute illness, especially fever. - Assess prior hepatitis A vaccination history to avoid unnecessary repeat dosing. - Consider the limited safety data in pregnancy; vaccination is generally avoided unless benefits outweigh risks. - Monitor for signs of anaphylaxis for at least 15 minutes after injection.

Havrix Junior may interact with other agents; the following considerations are recommended when co‑administering medications or vaccines.

Avoid: - Concurrent administration with live viral vaccines is generally avoided to prevent potential immune interference. - Do not give Havrix Junior to children receiving immunoglobulin therapy for hepatitis A prophylaxis, as it may reduce vaccine efficacy.

Use with caution: - Concurrent use of immunosuppressive drugs (e.g., corticosteroids) may diminish antibody response; timing should be coordinated. - Antipyretics such as acetaminophen can be used to manage post‑vaccination fever, but routine prophylactic use may blunt immune response. - If the child is on antiretroviral therapy, monitor hepatitis A antibody titres to confirm adequate seroconversion.